{
    "symbol": "BLRX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-15 15:11:03",
    "content": " With the funds received from these transactions, our cash balance at September 30, 2022 was $57.3 million, which included the additional potential amounts available to us under the debt financing agreement, we believe positions us very well financially to execute the targeted commercial launch that we are planning should affect to be approved. Data from the study demonstrated meaningful net cost savings with Motixafortide plus GCSF due to a significantly greater proportion of patients in the Motixafortide arm, successfully achieving mobilization of the optimal amount of stem cells following a single administration of Motixafortide and in only one apheresis sessions."
}